As Kelce's football career winds down after three Super Bowl wins and 13 seasons with the Kansas City Chiefs, he's putting ...

"He's an extremely valuable media personality in a polarized country. He appeals to everybody and almost everybody knows who ...

Adding another potential wrinkle to the industry’s work with China is the Biosecure Act, a piece of China-targeting national ...

The public's views of measles, mumps, and rubella (MMR) vaccine safety and effectiveness have dropped, as has willingness to ...

Johnson & Johnson’s $14.6 billion buyout of Intra-Cellular in the first mo | Of the top 10 biopharma M&A deals of 2025, six ...

Cartoonist and counterculture icon R. Crumb reflects on his remarkable life and work in a new interview from his home in the South of France.

When President Donald Trump declared in May that he wanted drug companies to voluntarily cut their prices, few pharmaceutical executives wanted to go first. Now, no one wants to be last – and risk the ...

In 2025, Anthropic will grow from $1 billion to $9 billion in ARR (annual recurring revenue). OpenAI, meanwhile, will go from ...

Objective This study aimed to examine whether biomarker tests—finger-prick, skin-prick and offline fractional exhaled nitric oxide (FeNO)—are acceptable and feasible as a guide to treatment decisions, ...

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

Travis Kelce is contemplating retirement after 13 seasons with the Chiefs, with his off-field career rapidly expanding into Hollywood and television. Insiders suggest a strong push towards Los Angeles ...

AI - or was it? Judging by customer use cases, the answer is: not yet. But that doesn't mean customers aren't pursuing AI aggressively. From AI readiness to robotics progress, here's what we learned ...